A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
Scott Kopetz(The University of Texas MD Anderson Cancer Center), Natalie Cook(The Christie NHS Foundation Trust), Van K. Morris(The University of Texas MD Anderson Cancer Center), Bert H. O’Neil(Indiana University Health), Mark Saunders(Manchester Academic Health Science Centre), Elspeth Asken(Redx Pharma (United Kingdom)), Janet Graham(Beatson West of Scotland Cancer Centre), Craig Tilston(Redx Pharma (United Kingdom)), John Bridgewater(University College London Hospitals NHS Foundation Trust), Eileen E. Parkes(Nuffield Orthopaedic Centre), Caroline Phillips(Redx Pharma (United Kingdom)), Louise Goodwin(Redx Pharma (United Kingdom)), Jane Robertson(Cancer Research UK), Simon A. Woodcock(Bio-Medical Science (South Korea))
Cited by 9
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k